Ueda T, Kumazawa J, Ohmori A, Sakamoto K, Aito K, Morita I, Ohta Y, Takesue T, Hara S, Sagiyama K
Dept. of Urology, Kyushu University Hospital.
Gan To Kagaku Ryoho. 1990 Feb;17(2):239-43.
Clinical effects of UFT chemotherapy for renal cancer were evaluated by 19 collaborating hospitals. UFT (300-600 mg/day) was administered for more than 3 months. Of the 30 patients entered in this study, 21 were evaluable for the antitumor effects of the drug. Of the 21 evaluable patients, complete response (CR) was obtained in 2 patients, partial response (PR) in 1, no change (NC) in 7, progressive disease (PD) in 11, respectively. The response rate was 0% in patients with primary lesion and 21.4% in nephrectomized patients with metastatic lesion. Responses were observed in the metastases of lung, pleura and mediastinal lymph node. The main side effects in 27 patients were gastrointestinal symptoms. No significant abnormality was noted on blood laboratory data. In one patient the drug was discontinued within 3 months because of gastrointestinal symptoms. These results suggested that UFT chemotherapy for advanced renal cancer was clinically effective.
19家合作医院评估了优福定（UFT）化疗对肾癌的临床疗效。给予优福定（每日300 - 600毫克），持续3个月以上。本研究纳入的30例患者中，21例可评估该药物的抗肿瘤效果。在这21例可评估患者中，2例获得完全缓解（CR），1例部分缓解（PR），7例病情无变化（NC），11例病情进展（PD）。原发灶患者的缓解率为0%，肾切除术后有转移灶患者的缓解率为21.4%。在肺、胸膜和纵隔淋巴结转移灶中观察到了反应。27例患者的主要副作用为胃肠道症状。血液实验室数据未发现明显异常。1例患者因胃肠道症状在3个月内停药。这些结果表明，优福定化疗对晚期肾癌具有临床疗效。
